First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen
Osaka University is starting a Phase I clinical trial (first in human) for refractory prostate cancer using an astatine-labeled drug ([At-211]PSMA-5). This trial aims to evaluate the safety, pharmacokinetics, and efficacy of the new alpha therapy. Previous trials for thyroid cancer have been successful. The trial addresses the high unmet needs of prostate cancer patients and leverages Japan's ability to manufacture astatine. This innovative therapy promises fewer side effects and no need for hospitalization, potentially benefiting patients globally.
Source: asiaresearchnews.com
